These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 31880233)

  • 1. Dissociating the Clinical Role and Economic Value of Intranasal Esketamine.
    Dadiomov D
    J Manag Care Spec Pharm; 2020 Jan; 26(1):20-22. PubMed ID: 31880233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effectiveness and Value of Esketamine for the Management of Treatment-Resistant Depression.
    Agboola F; Atlas SJ; Touchette DR; Fazioli K; Pearson SD
    J Manag Care Spec Pharm; 2020 Jan; 26(1):16-20. PubMed ID: 31880219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ketamine and Monoamine Oxidase Inhibitor Combination: Utility, Safety, Efficacy?
    Bottemanne H; Bonnard E; Claret A; Petit AC; Gaillard R; Fossati P
    J Clin Psychopharmacol; 2020; 40(6):636-638. PubMed ID: 33009225
    [No Abstract]   [Full Text] [Related]  

  • 4. Promises and concerns regarding the use of ketamine and esketamine in the treatment of depression.
    Pérez-Esparza R; Kobayashi-Romero LF; García-Mendoza AM; Lamas-Aguilar RM; Fonseca-Perezamador A
    Acta Psychiatr Scand; 2019 Aug; 140(2):182-183. PubMed ID: 31251388
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy of intravenous ketamine and intranasal esketamine with dose escalation for Major depression: A systematic review and meta-analysis.
    Seshadri A; Prokop LJ; Singh B
    J Affect Disord; 2024 Jul; 356():379-384. PubMed ID: 38537759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
    Daly EJ; Singh JB; Fedgchin M; Cooper K; Lim P; Shelton RC; Thase ME; Winokur A; Van Nueten L; Manji H; Drevets WC
    JAMA Psychiatry; 2018 Feb; 75(2):139-148. PubMed ID: 29282469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intranasal esketamine: A novel drug for treatment-resistant depression.
    Khorassani F; Talreja O
    Am J Health Syst Pharm; 2020 Aug; 77(17):1382-1388. PubMed ID: 32729898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program.
    Doherty T; Wajs E; Melkote R; Miller J; Singh JB; Weber MA
    CNS Drugs; 2020 Mar; 34(3):299-310. PubMed ID: 31994024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of intranasal esketamine for the treatment of major depressive disorder.
    Kryst J; Kawalec P; Pilc A
    Expert Opin Pharmacother; 2020 Jan; 21(1):9-20. PubMed ID: 31663783
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1).
    Fedgchin M; Trivedi M; Daly EJ; Melkote R; Lane R; Lim P; Vitagliano D; Blier P; Fava M; Liebowitz M; Ravindran A; Gaillard R; Ameele HVD; Preskorn S; Manji H; Hough D; Drevets WC; Singh JB
    Int J Neuropsychopharmacol; 2019 Oct; 22(10):616-630. PubMed ID: 31290965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching to Intranasal Esketamine Maintains the Antidepressant Response to Intravenous Racemic Ketamine Administration: A Case Series of 10 Patients.
    Banov MD; Landrum RE; Moore MB; Szabo ST
    J Clin Psychopharmacol; 2021 Sep-Oct 01; 41(5):594-599. PubMed ID: 34411009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Esketamine: A Novel Option for Treatment-Resistant Depression.
    Bozymski KM; Crouse EL; Titus-Lay EN; Ott CA; Nofziger JL; Kirkwood CK
    Ann Pharmacother; 2020 Jun; 54(6):567-576. PubMed ID: 31795735
    [No Abstract]   [Full Text] [Related]  

  • 13. Esketamine: A Drug to Treat Resistant Depression That Brings More Questions Than Answers.
    Mischel NA; Balon R
    J Clin Psychopharmacol; 2021 May-Jun 01; 41(3):233-235. PubMed ID: 33905639
    [No Abstract]   [Full Text] [Related]  

  • 14. The Concurrent Treatment With Intravenous Ketamine and an Irreversible Monoamine Oxidase Inhibitor for Treatment-Resistant Depression Without Hypertensive Crises.
    Wang JCC; Swainson J
    J Clin Psychopharmacol; 2020; 40(5):515-517. PubMed ID: 32740556
    [No Abstract]   [Full Text] [Related]  

  • 15. Esketamine nasal spray (Spravato) for treatment-resistant depression.
    Med Lett Drugs Ther; 2019 Apr; 61(1569):54-57. PubMed ID: 31169797
    [No Abstract]   [Full Text] [Related]  

  • 16. Esketamine for treatment resistant depression: a trick of smoke and mirrors?
    Gastaldon C; Papola D; Ostuzzi G; Barbui C
    Epidemiol Psychiatr Sci; 2019 Dec; 29():e79. PubMed ID: 31841104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Ketamine on Rumination in Treatment-Resistant Depressive Patients.
    Vidal S; Jermann F; Aubry JM; Richard-Lepouriel H; Kosel M
    J Clin Psychopharmacol; 2020; 40(6):607-610. PubMed ID: 33044358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic.
    Diamond PR; Farmery AD; Atkinson S; Haldar J; Williams N; Cowen PJ; Geddes JR; McShane R
    J Psychopharmacol; 2014 Jun; 28(6):536-44. PubMed ID: 24699062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacotherapy: Ketamine and Esketamine.
    Feeney A; Papakostas GI
    Psychiatr Clin North Am; 2023 Jun; 46(2):277-290. PubMed ID: 37149345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies.
    Doty RL; Popova V; Wylie C; Fedgchin M; Daly E; Janik A; Ochs-Ross R; Lane R; Lim P; Cooper K; Melkote R; Jamieson C; Singh J; Drevets WC
    CNS Drugs; 2021 Jul; 35(7):781-794. PubMed ID: 34235612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.